Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 747-754

  Quan, Yudong ^a   Brenner, Bluma G ^a   Oliveira, Maureen ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION;

HIV-1; HIV-1 REVERSE TRANSCRIPTASE; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037310042     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.747-754.2003     Document Type: Article

References (49)

1. Ait-Khaled, M., C. Stone, G. Amphlett, B. Clotet, S. Staszewski, C. Katlama, and M. Tisdale. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689.
2. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
3. Lys3 as primers in an endogenous HIV-1 in vitro reverse transcription/template switching reaction. J. Biol. Chem. 269:14672-14680.
4. Atkinson, B., J. Isaacson, M. Knowles, E. Mazabel, and A. K. Patick. 2000. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J. Infect. Dis. 182:420-427.
5. Back, N. K. T., M. Nijhuis, W. Keulen, et al. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
6. Bebenek, K., J. Abbotts, J. D. Roberts, S. H. Wilson, and T. A. Kunkel. 1989. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J. Biol. Chem. 264: 16948-16956.
7. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. A. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
8. Boyer, J. C., K. Bebenek, and T. A. Kunkel. 1992. Unequal human immunodeficiency virus type 1 reverse transcriptase error rates with RNA and DNA templates. Proc. Natl. Acad. Sci. USA 89:6919-6923.
9. Bruno, R., M. B. Regazzi, V. Ciappina, P. Villani, P. Sacchi, M. Montagna, R. Panebianco, and G. C. Filice. 2001. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin. Pharmacokinet. 40:695-700.
10. Cammack, N., P. Rouse, C. Marr, P. Reid, R. Boehme, J. Coates, C. Penn, and J. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
11. Devereux, H. L., M. Youle, M. A. Johnson, and C. Loveday. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13: F123-F127.
12. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
13. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
14. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
15. Gotte, M., D. Arion, M. A. Parniak, and M. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol 74:3579-3585.
16. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxy-cytidine. J. Virol. 66:7128-7135.
17. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. Wainberg. 1994. Identification of a codon 65 in the IKKK motif of reverse transcriptase that encodes M.A. human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
18. Ingrand, D., J. Weber, C. A. Boucher, C. Loveday, C. Robert, A. Hill, and N. Cammack. 1995. Phase I/Il study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. AIDS 9:1323-1329.
19. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contribute to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
20. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595.
21. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
22. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
23. Larder, B. A., K. E. Coates, and D. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
24. Larder, B. A., D. J. M. Purifoy, K. L. Powell, and G. Darby. 1987. Site specific mutagenesis of AIDS virus reverse transcriptase. Nature 327:716-717.
25. Le Grice, S. F. J., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
26. Le Grice, S. F. J., and F. Gruninger-Leitch. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314.
27. Lys3 in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site. J. Virol. 70:4996-5004.
28. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
29. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
30. Miller, V., T. Stark, A. E. Loeliger, and J. M. Lange. 2002. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 3:135-145.
31. Moore, K. H., J. E. Barrett, S. Shaw, G. E. Pakes, R. Churchus, A. Kapoor, J. Lloyd, M. G. Barry, and D. Back. 1999. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 13:2239-2250.
32. Pluda, J. M., T. P. Cooley, J. S. Montaner, et al. 1995. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
33. Quan, Y., C. Liang, P. Inouye, and M. A. Wainberg. 1998. Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. Nucleic Acids Res. 26:5692-5698.
34. Quan, Y., Z. Gu, X. Li, C. Liang, M. A. Parniak, and M. A. Wainberg. 1998. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. J. Mol. Biol. 277:237-247.
35. Quan, Y., Z. Gu, X. Li, Z. Li, C. D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
36. Quan, Y., L. W. Rong, C. Liang, and M. A. Wainberg. 1999. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J. Virol. 73:6700-6707.
37. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
38. Rodriguez, J. F., J. L. Rodriguez, J. Santana, H. Garcia, and O. Rosario. 2000. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob. Agents Chemother. 44:3097-3100.
39. Salomon, H., A. Belmonte, K. Nguyen, Z. Gu, M. Gelfand, and M. A. Wainberg. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
40. Schinazi, R., F. Lloyd, Jr., M.-H. Nguyen, et al. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
41. Solas, C., Y. F. Li, M. Y. Xie, J. P. Sommadossi, and X. Zhou. 1998. Intracellular nucleotides of (-)-2′,3′-deoxy-3′-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 42:2989-2995.
42. St Clair, M. H., J. L. Martin, G. Tudor-Williams, M. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to dideoxyinosine and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
43. Tatsunami, S., A. Ito, K. Kawata, R. Kuwabara, K. Fukutake, and K. Yam. 2000. Pharmacokinetic consideration on administration regimen of lamivudine in Japanese patients infected with HIV-1. Int. J. Clin. Pharmacol. Ther. 38:333-338.
44. Tisdale, M., S. D. Kemp, N. R. Parry, and B. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
45. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
46. Verhofstede, C., F. Van Wanzeele, B. Van der Gucht, N. De Cabooter, and J. Plum. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
47. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, et al. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271: 1282-1285.
48. Wainberg, M. A., M. D. Miller, Y. Quan, et al. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. 4:87-94.
49. Zack, J. A., S. J. Arrigo, S. R. Weitman, A. S. Go, A. Haislip, and I. S. Y. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61: 213-222.